Kiromic BioPharma (NASDAQ:KRBP) Stock Price Down 24.1%

Shares of Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) traded down 24.1% during mid-day trading on Tuesday . The company traded as low as $0.16 and last traded at $0.21. 1,794,606 shares changed hands during mid-day trading, an increase of 208% from the average session volume of 582,656 shares. The stock had previously closed at $0.28.

Kiromic BioPharma Trading Down 24.1 %

The stock’s 50-day simple moving average is $0.22 and its 200-day simple moving average is $0.31. The firm has a market capitalization of $3.33 million, a P/E ratio of -0.21 and a beta of 0.06.

Kiromic BioPharma (NASDAQ:KRBP – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.03. On average, equities research analysts expect that Kiromic BioPharma, Inc. will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kiromic BioPharma stock. Renaissance Technologies LLC purchased a new stake in shares of Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 56,111 shares of the company’s stock, valued at approximately $48,000. Renaissance Technologies LLC owned approximately 0.36% of Kiromic BioPharma at the end of the most recent quarter. 12.62% of the stock is owned by institutional investors.

Kiromic BioPharma Company Profile

(Get Rating)

Kiromic BioPharma, Inc, an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1.